Bacillus Calmette‐Guérin (BCG) showed no clear difference in serious adverse effects compared with mitomycin C (MMC) (low certainty).
Bacillus Calmette‐Guérin (BCG) showed no clear difference in time to recurrence (absolute effect size estimates based on event… compared with mitomycin C (MMC) (low certainty).
Bacillus Calmette‐Guérin (BCG) showed no clear difference in time to progression (absolute effect size estimates based on event… compared with mitomycin C (MMC) (low certainty).
Sorafenib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
Tivozanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
Sorafenib probably leads to higher progression‐free survival (absolute effect size estimates based on… compared with pazopanib (targeted agent versus targeted agent) (moderate certainty).
Sorafenib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with pazopanib (targeted agent versus targeted agent) (low certainty).
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).
Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with everolimus (targeted agent versus targeted agent) (low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
It is very uncertain whether sorafenib changes overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (moderate certainty).
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).